Photo-activated microtubule targeting drugs: Advancing therapies for colorectal cancer

doi:10.3748/wjg.v30.i26.3257

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 26

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2722)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

197

HTML

1887

Sum=2084

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

124

Download

374

Sum=498

Jul 14, 2024 (publication date) through Oct 30, 2025

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastroenterol. Jul 14, 2024; 30(26): 3257-3260
Published online Jul 14, 2024. doi: 10.3748/wjg.v30.i26.3257

Photo-activated microtubule targeting drugs: Advancing therapies for colorectal cancer

Naresh Singh, Samantha Sharma

Naresh Singh, Samantha Sharma, Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, United States

Author contributions: Singh N and Sharma S conceived the idea and wrote the manuscript; Singh N and Sharma S contributed equally to the manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Samantha Sharma, PhD, Research Scientist, Department of Medical and Molecular Genetics, Indiana University School of Medicine, 980 W Walnut Street, R3.C260, Indianapolis, IN 46202, United States. samshar@iu.edu

Received: April 16, 2024
Revised: June 11, 2024
Accepted: June 24, 2024
Published online: July 14, 2024
Processing time: 84 Days and 10.4 Hours

Core Tip

Core Tip: While progress has been made in colorectal cancer (CRC) treatment, significant challenges remain, as highlighted by the persistently low five-year survival rate. Integrating chemotherapy with other targeted therapies has shown promise, particularly in immune cold microsatellite stable or mutation-related CRCs. The emergence of personalized medicine, leveraging photo-switchable microtubule (MT)-targeted drugs, represents a novel approach in CRC management. While traditional MT-targeted drugs like taxanes have shown limited efficacy in CRC, optically controlled MT-drugs hold potential for improving treatment outcomes in CRC patients.